Ministry of Tribal Affairs, CSIR and IGIB Organized Workshop on “BIRSA 101” — India’s First Indigenous CRISPR-Based Gene Therapy for Sickle Cell Disease

1. At a Glance

• BIRSA 101 is India's first indigenous CRISPR-Cas9 based gene therapy for Sickle Cell Disease (SCD), developed by CSIR-Institute of Genomics & Integrative Biology (IGIB), New Delhi [1][3].
• Named in honour of Bhagwan Birsa Munda, the tribal freedom fighter; targets a disease disproportionately afflicting India's tribal population in central/eastern India [1][3].
• Workshop on "BIRSA 101" was organised by Ministry of Tribal Affairs + CSIR + CSIR-IGIB on 14 May 2026 at CSIR-IGIB, New Delhi, under Janjatiya Garima Utsav 2026 [1].
• Significant for UPSC because it links GS-III (biotechnology, indigenous innovation, health) with GS-II (tribal welfare, SCD Elimination Mission) and GS-I (tribal society).

2. Why in the News

• 14 May 2026: workshop on BIRSA 101 held at CSIR-IGIB, New Delhi during the month-long Janjatiya Garima Utsav 2026 [1].
• November 2025: CSIR-IGIB executed a technology transfer agreement with Serum Institute of India (Pune) for clinical translation and upscaling [3].
• Earlier launched by Union Minister Dr. Jitendra Singh as India's first indigenous CRISPR-based gene therapy for SCD [3][5].

3. Background & Evolution

• 2023 Union Budget: Government announced National Sickle Cell Anaemia Elimination Mission (NSCAEM) [2].
• 1 July 2023: NSCAEM launched by the PM at Shahdol, Madhya Pradesh [2].
• Goal: eliminate SCD by 2047; universal screening of 7 crore individuals aged 0-40 years in tribal areas by FY 2025-26 [2].
• Implemented across 17 high-focus tribal states: Gujarat, Maharashtra, Rajasthan, MP, Jharkhand, Chhattisgarh, West Bengal, Odisha, Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Assam, UP, Kerala, Bihar, Uttarakhand [2].
• As on 31 July 2025: 6.07 crore screenings; 2.15 lakh diagnosed, 16.7 lakh carriers identified [2].
• Nov 2025: Tech-transfer to Serum Institute for commercialisation [3].
• May 2026: BIRSA 101 workshop under Janjatiya Garima Utsav [1].

4. Core Static Facts

• Therapy name: BIRSA 101 (after Birsa Munda) [1].
• Technology: CRISPR-Cas9 genome editing ("precise genetic surgery") [1][3].
• Developer: CSIR-IGIB, an Institute of the Council of Scientific and Industrial Research, under Ministry of Science & Technology (DSIR) [1][3].
• Industry partner: Serum Institute of India, Pune (MoU Nov 2025) [3].
• Lead Ministry for workshop: Ministry of Tribal Affairs; collaboration with CSIR & CSIR-IGIB [1].
• Linked mission: National Sickle Cell Anaemia Elimination Mission (2023) — target year 2047 [2].
• Cost angle: Comparable foreign therapies priced at ₹20–25 crore; BIRSA 101 aims at a fraction of that [3].
• Festival vehicle: Janjatiya Garima Utsav 2026 — month-long celebration marking Birsa Munda Jayanti (15 Nov) tradition, aligned to Viksit Bharat vision [1].

5. Multi-Dimensional Analysis

Scientific / Technological

• Uses CRISPR-Cas9 — adapts the 2020 Nobel-winning gene-editing toolkit; enhanced Cas9 variant developed jointly by CSIR-IGIB and LVPEI claimed more precise & efficient than existing systems [3].
• Demonstrates Atmanirbhar Bharat in frontline medical biotechnology; reduces dependence on imported therapies (e.g., Casgevy) [3].

Social (Tribal)

• SCD prevalence highest among tribal communities of central & eastern India (Chhattisgarh, Jharkhand, Odisha, MP) [2][3].
• Aligns with constitutional safeguards under Articles 342, 275(1), 46 for Scheduled Tribes.

Economic / Health Financing

• Slashes treatment cost from ~₹20-25 crore abroad → affordable domestic option, easing out-of-pocket health expenditure [3].

Ethical / Governance

• Raises bioethics issues (somatic vs germline editing, consent in tribal populations); requires CDSCO/ICMR regulatory oversight.

Administrative

• Inter-ministerial: MoTA + M/o Health & Family Welfare + M/o S&T; rides on Ayushman Bharat-HWCs for screening & follow-up [2].

6. Recent Developments (last 12-18 months)

• 31 July 2025: NSCAEM crosses 6.07 crore screenings milestone [2].
• November 2025: CSIR-IGIB–Serum Institute technology transfer agreement for BIRSA 101 [3].
• 14 May 2026: MoTA + CSIR + CSIR-IGIB workshop on BIRSA 101 under Janjatiya Garima Utsav 2026 [1].
• Earlier launch by Dr. Jitendra Singh of India's first indigenous CRISPR therapy for SCD [3][5].
• National Biobank & Longitudinal Population Data Study inaugurated at CSIR-IGIB by Dr. Jitendra Singh — feeder ecosystem for genomic medicine [4].

7. Prelims Hooks

• BIRSA 101 is named after Birsa Munda, tribal icon born 15 Nov 1875 [1].
• Developed by CSIR-IGIB, New Delhi — not AIIMS, not ICMR [1][3].
• Uses CRISPR-Cas9 gene-editing platform [1][3].
• Industry partner for commercialisation: Serum Institute of India (MoU Nov 2025) [3].
• NSCAEM launched 1 July 2023 at Shahdol, Madhya Pradesh by PM Modi [2].
• NSCAEM target: SCD elimination by 2047; screen 7 crore people (0-40 yrs) by FY 2025-26 [2].
• NSCAEM covers 17 states [2].
• As on 31.07.2025: 6.07 crore screened, 2.15 lakh diagnosed, 16.7 lakh carriers [2].
• Janjatiya Garima Utsav is celebrated annually (linked to Birsa Munda Jayanti, 15 Nov — also Jharkhand Foundation Day) [1].
• CSIR is under Ministry of Science & Technology (DSIR) — not under Health Ministry [3].
• BIRSA 101 envisaged to undercut overseas SCD gene therapies costing ₹20-25 crore [3].
• CSIR-IGIB also developed India's first CRISPR-based COVID-19 test ("Feluda") with Tata Group [6].

8. Mains Relevance

• GS-III: "Awareness in fields of Biotechnology; indigenous technology and developing new technology."
• GS-II: "Welfare schemes for vulnerable sections (STs); issues relating to health."
• GS-I: "Salient features of Indian Society; diversity; tribal communities."

Probable question stems

1. "India's BIRSA 101 marks a paradigm shift from symptom management to curative gene therapy in Sickle Cell Disease. Examine its scientific, social and ethical implications."
2. "Discuss how indigenous biotechnology innovations like CRISPR-based therapies can advance both 'Atmanirbhar Bharat' and tribal welfare."
3. "Critically evaluate the progress of the National Sickle Cell Anaemia Elimination Mission in achieving its 2047 target."

9. Related Topics to Study Next

• NSCAEM (2023) — operational vehicle for SCD elimination [2].
• CRISPR-Cas9 technology — Nobel 2020; ethical debates.
• PM-JANMAN & DAJGUA schemes — tribal welfare convergence.
• Ayushman Bharat-HWCs — screening platform for SCD [2].
• National Biobank & Longitudinal Population Study at IGIB — genomic medicine backbone [4].
• Feluda Test — earlier CRISPR product from CSIR-IGIB [6].
• Janjatiya Gaurav Divas (15 Nov) — Birsa Munda Jayanti.
• DBT's Cell & Gene Therapy mission — regulatory/funding ecosystem [7].

10. Common Errors / Trap Areas

• Wrong ministry: BIRSA 101 development = M/o Science & Technology (CSIR-IGIB), NOT Ministry of Health or Ministry of Tribal Affairs (MoTA only co-hosted the workshop).
• NSCAEM launch state: Launched at Shahdol, MP, not Jharkhand or Chhattisgarh [2].
• 2047, not 2030, is the SCD elimination target [2].
• CRISPR ≠ stem-cell transplant: BIRSA 101 is gene-editing, distinct from allogeneic HSC transplant.
• Janjatiya Garima Utsav vs Janjatiya Gaurav Divas — Utsav is the month-long festival; Gaurav Divas is 15 Nov (Birsa Munda's birth anniversary, declared in 2021).
• IGIB is in New Delhi, not Hyderabad (don't confuse with CCMB).